BioStem Technologies, Inc. (BSEM)
BSEMNASDAQ-CMBiotechnology: Biological Products (No Diagnostic Substances)
$0.9350
-0.0349 (-3.60%) today
Pre-market, Nov 17, 4:00 PM ET
- Market cap
- $17.93m
- P/E
- –
- EPS, last 4 quarters
- $-1.58
- Dividend yield
- –
- Day range
- –
- 52-week range
- $0.9000 to $5.44
- Average volume
- –
- Previous close
- $0.9699
Analysts
1 coveringBuy1 buy, 0 hold, 0 sell
Targets a year out average $7.00, +648.7% from here
Earnings
next estimate $-0.4500Next report
Dec 2025
-150.0%
Mar 2026
-85.7%
Jun 2026
-4.0%
Sep 2026
-23.3%
estimate reported, and the surprise
News
8 latest- BioStem Technologies, Inc. Reports Third Quarter 2026 Financial Results and Raises Full-Year Revenue GuidanceFintel · 5 days ago
- BioStem (BSEM) Q3 2026 Earnings Call TranscriptThe Motley Fool · 5 days ago
- BioStem Technologies, Inc. (BSEM) Reports Q3 Loss, Beats Revenue EstimatesZacks · 6 days ago
- Certara, Inc. (CERT) Tops Q3 Earnings and Revenue EstimatesZacks · Nov 5, 2026
- BioStem Secures Up To $40 Mln Committed Equity Facility RTTNews · Sep 19, 2026
- BioStem Technologies Expands Hospital Access For VENDAJE And VENDAJE AC Through Vizient And Premier RTTNews · Sep 4, 2026
- BioStem Q2 Revenue Rises 29%; Raises 2026 Guidance, Uplists To Nasdaq RTTNews · Aug 20, 2026
- BioStem Technologies, Inc. (BSEM) Reports Q2 Loss, Beats Revenue EstimatesZacks · Aug 12, 2026
The company
BioStem Technologies, Inc. is a publicly traded, biomedical innovator, focused on developing, manufacturing and commercializing advanced allograft solutions derived from perinatal tissue. The company leverages its industry-leading proprietary BioRetain, CryoTek and SteriTek processing technologies, designed to optimize the preservation of the natural properties of these tissues, supporting their use in clinical settings. Its allografts are used by clinicians across a wide range of specialties. With a growing portfolio of products, expanding clinical research initiatives, and a national commercial footprint, BioStem is committed to advancing innovation in regenerative medicine.
- Sector
- Health Care
- Industry
- Biotechnology: Biological Products (No Diagnostic Substances)
- Exchange
- NASDAQ-CM
- Region
- North America
- Website
- www.biostemtech.com
Often looked at with it
Figures from Yahoo, Nasdaq (Zacks consensus) and Lighter. Stocks can be minutes behind. Nothing here is advice.